GlassScriptPhysician profile
Yoojin Sohn
NPI 1548624869
$3,746.08
in general payments reported to CMS, 2019-2025
38 companies · $1,857 in 2025
The $1,857 reported for 2025 was more than what 75% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $63.75 · 2021: $135 · 2022: $123 · 2023: $625 · 2024: $942 · 2025: $1,857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,424.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,423.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $390.17 | 2023-2025 | Tepezza, Evenity, Prolia |
| Novo Nordisk INC | $374.08 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Cequr Corporation | $278.63 | 2023-2025 | Cequr Simplicity |
| Xeris Pharmaceuticals, INC. | $274.88 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Corcept Therapeutics | $258.57 | 2021-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $202.06 | 2023-2025 | |
| Medtronic, INC. | $181.77 | 2023-2025 | Minimed 780g, Intellis Adaptivestim |
| Mannkind Corporation | $174.16 | 2021-2025 | Afrezza |
| Lilly USA, LLC | $158.93 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Dexcom, INC. | $147.22 | 2021-2025 | Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $125.00 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.30 | 2024-2025 | Jardiance |
| Abbvie INC. | $93.53 | 2021-2025 | |
| Beta Bionics, INC. | $91.70 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Ascensia Diabetes Care US INC. | $82.98 | 2023-2024 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $78.88 | 2023-2025 | Freestyle Libre 3 |
| Ionis Pharmaceuticals, INC. | $63.99 | 2025 | Tryngolza |
| Medtronic Minimed, INC. | $63.75 | 2020 | |
| Insulet Corporation | $63.15 | 2023-2024 | Omnipod |
| Radius Health, INC. | $50.56 | 2025 | Tymlos |
| Sequel Med Tech, LLC | $46.68 | 2025 | Twiist |
| Pfizer INC. | $43.26 | 2024 | |
| Glaxosmithkline, LLC. | $35.64 | 2025 | Shingrix, Arexvy |
| Horizon Therapeutics Plc | $30.84 | 2023 | Tepezza |
| Averitas Pharma INC. | $30.29 | 2025 | Qutenza |
| Bayer Healthcare Pharmaceuticals INC. | $29.22 | 2021-2025 | |
| Rhythm Pharmaceuticals, INC. | $28.97 | 2025 | Imcivree |
| Recordati_rare_diseases_inc. | $25.54 | 2025 | Isturisa |
| Madrigal Pharmaceuticals | $25.46 | 2025 | Rezdiffra |
| Ibsa Pharma INC. | $21.27 | 2025 | Flector, Licart, Tirosint |
| Alexion Pharmaceuticals, INC. | $21.14 | 2025 | Strensiq |
| Acella Pharmaceuticals, LLC | $21.13 | 2025 | NP Thyroid 60 |
| Vivus LLC | $21.12 | 2024 | Qsymia |
| Ascendis Pharma Endocrinology INC | $20.36 | 2024 | |
| Kyowa Kirin, INC. | $20.10 | 2025 | |
| Amneal Pharmaceuticals LLC | $19.47 | 2024 | Unithroid |
| Organon LLC | $18.88 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $13.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yoojin Sohn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.